AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03779360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
Study NCT03779360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
Study NCT00743145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Marijuana (6.2% THC)
Description: Marijuana cigarette containing 6.2% THC
Study NCT00743145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active Marijuana (6.2% THC)
Description: Marijuana cigarette containing 6.2% THC
Study NCT00743145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone (12mg/70kg)
Study NCT00743145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone (12mg/70kg)
Study NCT03552458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri Oral Solution [BioGaia]
Description: BioGaia Lactobacillus Reuteri drops
Study NCT03552458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
Study NCT03274271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action planning
Description: Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
Study NCT00743145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo naltrexone
Description: Naltrexone (0mg)
Study NCT03569176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autism Glass
Description: The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
Study NCT03569176 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Autism Glass
Description: The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
Study NCT03274271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping planning
Description: Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
Study NCT03274271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Self-monitoring is the behaviour change technique used to make users keep track of their goal.
Study NCT03274271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback and tips
Description: In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
Study NCT03274271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback and tips
Description: In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT04294264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT04294264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT03215030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.
Study NCT03602729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education
Description: Breastfeeding education in three different forms: written/verbal/video
Study NCT00723931 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
Study NCT05400915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Variltinib, Paclitaxel
Description: Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.
Study NCT03164577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drum-Assisted Recovery Therapy for Native Americans (DARTNA)
Description: An intervention that utilizes AI/AN drumming as its core component of treatment.
Study NCT03164577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Plus
Description: Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
Study NCT01483768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy for morbid obesity
Description: Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
Study NCT02988154 — intervention group
Intervention type: OTHER
Intervention: Simulation training
Description: Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
Study NCT02988154 — intervention group
Intervention type: OTHER
Intervention: ''See one, do one'' approach
Description: The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
Study NCT04422743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline 500 mg plus Homotaurine 50 mg
Description: Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
Study NCT03368482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Gym Exercises
Description: Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine.
Study NCT03368482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise program for institutionalized older adults.
Description: Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
Study NCT02069951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice a procedural module on a simulator
Study NCT00746460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVD risk profile
Description: Cardiovascular risk assessment and behavioral counselling
Study NCT01279915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0456
Description: oral
Study NCT01279915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01209988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4mg
Description: perioperative tamsulosin 0.4mg daily for three weeks
Study NCT01209988 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No medication
Description: No medication
Study NCT01385423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative Regimen
Description: Fludarabine 25 mg/m\^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (\*if \< 4 months from prior transplant, omit day -4 dose)
Study NCT01385423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Recombinant Human IL-15 (rhIL-15)
Description: IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
Study NCT01985724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
Study NCT01985724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
Study NCT01289405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
Study NCT01289405 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
Study NCT01833975 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Transplantation of Autologous stem cell [MNCs] .
Description: Intra thecal transplantation of Autologous stem cell \[MNCs\],100millions per dose in 3 divided doses at interval of 10 days.
Study NCT05080920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosmalip®
Description: Nutritional Supplement+Usual Care
Study NCT05080920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo+Usual Care
Study NCT02481882 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
Study NCT02481882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prohance (Gadoteridol)
Description: A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
Study NCT00716573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 0,75 mg bid, 24 months
Study NCT01985724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Study NCT01985724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
Study NCT01985724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
Study NCT01985724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoruracil
Description: ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Study NCT02925871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-designed person-centred care transitions
Description: The intervention consists of several elements that aim to meet patients', significant others', and professionals' needs for shared understanding, patient preparedness for homecoming, and coordination.
Study NCT02925871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current care transitions
Description: Control group participants will receive current care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
Study NCT03215030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone.
Study NCT02800902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral prophylaxis followed by placement of placebo gel
Study NCT02800902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Oral prophylaxis followed by placement of rosuvastatin gel
Study NCT02800902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Oral prophylaxis followed by placement of atorvastatin gel
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV
Study NCT01911221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
Study NCT00525057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Given SC
Study NCT03967561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive water-based aerobic training
Description: The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
Study NCT03967561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-progressive aerobic training
Description: The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
Study NCT02369523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
Study NCT02369523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine cocktail (PIC)
Description: 400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
Study NCT02369523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine
Study NCT03007342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet
Study NCT03007342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03505645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular infiltration
Description: The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~Treatment group 1: Periarticular infiltration~Intra-operatively after bone cuts have been made and prior to implant cementation, the multimodal injection will be infiltrated around the knee at 6 specific sites:~1. Medial femoral condyle periosteum~2. Medial gutter~3. Lateral femoral condyle periosteum~4. Lateral gutter~5. Posteromedial capsule~6. Posterolateral capsule
Study NCT03505645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular infiltration
Description: The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~After implant cementation and watertight joint capsular closure, the multimodal injection will be injected intra-articularly through the closed capsule.
Study NCT00680693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: 8 weekly 2-hour classes
Study NCT00680693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational support group for women with IBS
Description: 8 weekly 2-hour meetings
Study NCT01403844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carotenoid Depletion
Description: Depletion of carotenoids using a restricted food list
Study NCT02103218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education, activities, empowerment, racial pride building
Description: Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
Study NCT02103218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health education, activities
Description: Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
Study NCT06072248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks
Study NCT06072248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks
Study NCT06072248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscopy
Description: Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
Study NCT06072248 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ventilator
Description: ventilator
Study NCT06072248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator
Description: ventilator
Study NCT03676335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA eye gel
Description: The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
Study NCT01403844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carotenoid Repletion
Description: Carotenoid repletion with provided diet based on dietary guidelines.
Study NCT01403844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carotenoid Depletion
Description: Carotenoid depletion using a restricted food list.
Study NCT01403844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Natural Repletion
Description: Resumption of usual personal diet regimen. No restrictions.
Study NCT03782948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard gait training on BART without pelvic perturbations
Description: The Balance Assisted Robot on Treadmill (BART) enables various types of gait training on treadmill with visual feedback. It interfaces to the pelvis of the walking subject in an actuated and admittance-controlled manner, thus providing transparent haptic interaction with negligible power transfer.
Study NCT03782948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotised gait training with BART with pelvic perturbations
Description: In addition to the standard gait training, the BART will deliver perturbations in the forward/backward and left/right direction.
Study NCT03676335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA for eye emulsion
Description: The CsA for eye emulsion of 0.4 ml: 0.2 mg
Study NCT03676335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypromellose Eye Drops
Description: Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop